文献速递神经眼科

特发性颅内压增高治疗试验纵向研究:第6至12个月的结果

The Longitudinal Idiopathic Intracranial Hypertension Trial: Outcomes From Months 6-12.
PubMed 文献 · Am J Ophthalmol · 2017-01-17

本研究为IIHTT的非随机临床研究,96名受试者在6个月时从研究药物转为乙酰唑胺(ACZ)或无治疗,分为ACZ至ACZ组(n=34)、安慰剂至ACZ组(n=35)、ACZ至无治疗组(n=16)、安慰剂至无治疗组(n=11),评估6至12个月视野平均偏差(MD)等变化。结果显示所有组MD继续改善,安慰剂后加用ACZ组视乳头水肿分级、头痛和生活质量显著改善。

要点

  • ACZ至ACZ组MD改善0.35 dB(P=0.05),安慰剂至无治疗组改善0.81 dB(P=0.07)。
  • 安慰剂换用ACZ组视乳头水肿分级平均改善0.91单位(P<0.001)。
  • 安慰剂加用ACZ组生活质量和头痛残疾评分显著改善。

核心结论

  • IIHTT中所有治疗组从第6个月至第12个月MD继续改善,以逐渐停用研究药物的安慰剂组最为明显。
  • 安慰剂组加用ACZ后视乳头水肿分级、头痛和生活质量指标显著改善。

研究设计与样本

  • IIHTT为非随机临床研究,受试者曾随机分配至安慰剂加饮食或最大耐受剂量乙酰唑胺加饮食,6个月时转为ACZ或无治疗。
  • 共96名IIHTT受试者在6和12个月接受评估,分为ACZ至ACZ组(n=34)、安慰剂至ACZ组(n=35)、ACZ至无治疗组(n=16)、安慰剂至无治疗组(n=11)。
  • 主要结局为6至12个月视野平均偏差(MD)变化,次要结局包括视乳头水肿分级、ETDRS评分和生活质量(QoL)指标变化。

主要发现

  • ACZ至ACZ组MD改善0.35 dB(P=0.05),安慰剂至无治疗组MD改善0.81 dB(P=0.07)。
  • 其他组MD改善0.35-0.46 dB。
  • 安慰剂换用ACZ组视乳头水肿分级平均改善最明显,为0.91单位(P<0.001)。
  • 安慰剂加用ACZ组生活质量和头痛残疾评分显著改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether the beneficial effects of acetazolamide (ACZ) in improving vision at 6 months continues to month 12 in participants of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). DESIGN: Nonrandomized clinical study. METHODS: In the IIHTT, subjects were randomly assigned to placebo-plus-diet or maximally tolerated dosage of acetazolamide-plus-diet. At 6 months subjects transitioned from study drug to ACZ. This resulted in the following groups: (1) ACZ to ACZ; n = 34; (2) placebo to ACZ; n = 35; (3) ACZ to no treatment; n = 16; and (4) placebo to no treatment; n = 11. Ninety-six IIHTT subjects had evaluations at 6 and 12 months. Our main outcome measure was change from month 6 to month 12 in visual field mean deviation (MD) with secondary measures being change in papilledema grade, ETDRS scores, and quality-of-life (QoL) measures. RESULTS: The ACZ to ACZ group improved 0.35 dB, P = .05; placebo subjects with no ACZ improved 0.81 dB MD, P = .07 at 12 months. The other groups improved 0.35-0.46 dB MD. Mean improvements in papilledema grade occurred most markedly in the group that exchanged placebo for ACZ (0.91 units, P < .001). QoL and headache disability scores showed significant improvements in the placebo group with added ACZ. CONCLUSION: Improvements in MD continued from month 6 to month 12 of the IIHTT in all treatment groups, most marked in the placebo group tapered off study drug. Adding ACZ to the placebo group significantly improved papilledema grade, headache, and QoL measures.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wall M, Kupersmith MJ, Thurtell MJ, et al. The Longitudinal Idiopathic Intracranial Hypertension Trial: Outcomes From Months 6-12. Am J Ophthalmol. 2017. PMID: 28104417. doi:10.1016/j.ajo.2017.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。